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Abstract We investigated the effect of the dietary flavonoid
apigenin on myofibroblast function. We report that in myofibro-
blasts treated with apigenin, proliferation and basal levels of
K1(I) collagen and K-smooth muscle actin mRNAs were
markedly reduced. Apigenin also attenuated the transforming
growth factor-L-stimulated increases of K1(I) collagen and
K-smooth muscle actin mRNAs. Characterization of the apigenin
effects indicates that apigenin reduces both the stability of the
K1(I) collagen mRNA and the rate of transcription of the
K1(I) collagen gene through a cycloheximide-sensitive pathway.
Western blot analyses indicate that Akt activity is reduced in
apigenin-treated myofibroblasts. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Flavonoids are diphenyl propanoids found in edible plants
and are categorized as £avonols, £avones, catechins, £ava-
nones, anthocyanidins, and iso£avonoids. Flavonoids display
anti-proliferative and anti-in£ammatory properties [1^3]. For
example, quercetin (3,3P,4P,5,7-pentahydro£avone) has been
reported to relieve pain, lower body temperature, and inhibit
viral uncoating [4]. The activities of enzyme systems involved
in the initiation and maintenance of the in£ammatory and
immune responses are modulated by £avonoids. These include
serine and threonine protein kinases, phospholipases, lipoxy-
genase, and cyclooxygenase [4^8]. Flavonoids are also potent
inhibitors of processes involved in mitogen signaling and
DNA synthesis, including mitogen activation of receptor ty-
rosine kinases [9,10], protein kinase C [11,12] and topoisomer-
ase II [13]. Flavopiridol, a novel semisynthetic £avone ana-
logue of rohitukinean, is currently undergoing phase II trials
for the treatment of a variety of malignancies [14,15].
Apigenin (4P,5,7-trihydroxy£avone), a common dietary £a-
vonoid, is a non-toxic and non-mutagenic £avone. Apigenin
a¡ects a variety of cellular processes related to cell prolifer-
ation, including inhibition of mitogen-activated protein
(MAP) kinase [16] and phosphoinositol-3 kinase (PI3K). Api-
genin markedly inhibits the migration of endothelial cells and
capillary formation in vitro, independently of its inhibition of
hyaluronidase activity [17]. As an inhibitor of cell prolifera-
tion, apigenin may play a role in the prevention of carcino-
genesis. Apigenin at concentrations of 1^80 WM induces
growth inhibition and cell loss in cultures of colonic tumor
cells [18]. Moreover, apigenin suppresses 12-O-tetradecanoyl-
phorbol-13-acetate-mediated tumor promotion of mouse skin
[19]. Apigenin has been shown to induce cell cycle arrest in
both epidermal cells and ¢broblasts and to inhibit skin tu-
morigenesis in murine models [19]. Intraperitoneal administra-
tion of apigenin at the time of injection of B16-BL6 cells into
syngeneic mice, results in a signi¢cant, dose-dependent delay
of tumor growth, without toxicity [20].
In ¢brotic diseases, deposition of extracellular matrix is
modulated by increases in cell numbers as well as by regula-
tion of transcription, translation and post-translational mod-
i¢cations. The anti-proliferative and anti-in£ammatory e¡ects
of apigenin suggest that apigenin may modulate processes
involved in ¢brogenesis. Speci¢cally, apigenin may modulate
myo¢broblast functions. We found that in human lung myo-
¢broblasts, apigenin blocked thymidine incorporation and re-
duced basal and transforming growth factor-L (TGF-L)-
stimulated levels of K-smooth muscle actin mRNA and
K1(I) collagen mRNA.
2. Materials and methods
2.1. Materials
Apigenin (Calbiochem) and LY294002 (Calbiochem) were reconsti-
tuted at 5 mg/ml in dimethyl sulfoxide (DMSO). [3H]thymidine was
purchased from NEN DuPont (Boston, MA, USA). Recombinant
porcine TGF-L was purchased from RpD Systems (Minneapolis,
MN, USA). Anti-AKT antibodies (New England Biolabs), anti-phos-
pho-serine473-AKT antibodies (New England Biolabs), anti-phopho-
Erk1/2 antibodies (Upstate Biotechnology), and anti-Erk1/2 antibod-
ies (Upstate Biotechnology) were used according to manufacturer’s
instructions.
2.2. Tissue culture
Human embryonic lung ¢broblasts (IMR-90, Institute for Medical
Research, Camden, NJ, USA) were grown in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) supplemented with 0.37 g sodium bicarbon-
ate/100 ml, 10% (v/v) fetal bovine serum (FBS), 100 U penicillin/ml,
10 Wg streptomycin/ml, 1 mM sodium pyruvate, and 0.1 mM non-
essential amino acids. After con£uence, the serum content of the
medium was reduced to 0.4% FBS. Experimentation was performed
with ¢broblasts that had undergone less than 35 population doublings
and presented no evidence of senescence by light microscopy.
2.3. Nuclear run-on assay
Con£uent, quiescent ¢broblasts were washed twice with Puck’s sa-
line and scraped into a lysis bu¡er (10 mM Tris^HCl pH 7.4, 10 mM
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NaCl, 3 mM MgCl2, 0.5% NP-40). Following two low-speed spins,
the pellet was reconstituted in glycerol bu¡er (50 mM Tris^HCl pH
8.3, 40% glycerol, 5 mM MgCl2, 0.1 mM EDTA). In vitro labeling of
nascent RNA and hybridization with cDNA immobilized on nitro-
cellulose ¢lters was performed according to the methods reported
previously [21,22].
2.4. Western blotting
PAGE was performed under reducing conditions using 10% poly-
acrylamide gels as described [23]. Samples (100 Wg) for SDS^PAGE
and Western blotting were prepared from the cell layer of quiescent
con£uent ¢broblasts grown in 100-mm tissue culture dishes. The cell
layer was dissolved in RIPA bu¡er (1% NP-40, 0.5% sodium deoxy-
cholate, 0.1% SDS, 1 mM Na3VO4, 1 Wg/ml leupeptin, 1 WM phenyl-
methylsulfonyl £uoride, and 600 nM okadaic acid in phosphate-bu¡-
ered saline (PBS) and centrifuged (12 000Ug for 20 min) at 4‡C.
Protein concentrations were determined by Bradford assay. Gels
were transferred to nitrocellulose ¢lters (Schleicher and Schuell) and
blocked according to manufacturer’s speci¢cations [23].
2.5. Luciferase assay
IMR-90 myo¢broblasts were plated in 6-well plates (350 000/well)
in DMEM supplemented with 10% FBS. After 24 h, the cultures
were washed with PBS and incubated with the 3TP-LUX reporter
(1 Wg/well) mixed with Lipofectamine Plus according to manufactur-
er’s instructions (Gibco Life Technologies, Rockville, MD, USA) for
3 h. The transfection medium was replaced with DMEM supple-
mented with 10% FBS without antibiotics and the cultures were in-
cubated for an additional 20 h. The cultures were incubated in 0.4%
FBS without antibiotics for 16 h before experimentation.
3. Results
Our focus was to determine the e¡ect of apigenin on the
maintenance of the myo¢broblast phenotype. As an in vitro
model, we used primary human lung ¢broblasts (IMR-90)
that constitutively express both type I collagen and K-smooth
muscle actin, thus characterizing them as myo¢broblasts [24].
We determined the e¡ect of apigenin on cellular proliferation.
The cultures were treated with varying doses of apigenin for
24 h, then assayed for thymidine incorporation as previously
described [25]. We found that apigenin blocked thymidine
incorporation in a dose-dependent manner, with 200 nM api-
genin having no e¡ect and 20 WM apigenin inducing a max-
imal e¡ect (Fig. 1). We found that concentrations of apigenin
higher than 30 WM with a ¢nal concentration of 0.1% DMSO
formed a precipitate when added to the tissue culture medium.
To investigate the e¡ect of apigenin on the myo¢broblast
phenotype, we assessed the e¡ect of apigenin on steady-state
levels of K1(I) collagen mRNA and K-smooth muscle actin
mRNA in both quiescent and growth factor-stimulated myo-
¢broblasts. Northern blot analyses indicate that quiescent myo-
¢broblasts constitutively express low levels of K1(I) collagen
mRNA. Stimulation with TGF-L induced an increase of K1(I)
collagen mRNA steady-state levels. Following treatment with
20 WM apigenin for 24 h, the basal level of K1(I) collagen
mRNA was reduced and the TGF-L-stimulated increase of
K1(I) collagen mRNA was attenuated (Fig. 2a). A similar
pattern of expression was observed with K-smooth muscle
actin mRNA. Quiescent myo¢broblasts constitutively express
K-smooth muscle actin and stimulation with TGF-L induced
an increase of steady-state levels. As observed with K1(I) col-
lagen mRNA, treatment with apigenin decreased basal levels
of K-smooth muscle actin mRNA and attenuated the TGF-L-
stimulated increase of K-smooth muscle actin mRNA (Fig.
2b). In contrast, we found that apigenin did not alter basal
or TGF-L-stimulated levels of connective tissue growth factor
(CTGF) mRNA (data not shown).
The decrease of basal K1(I) collagen mRNA by apigenin is
time-dependent (Fig. 3). Quiescent myo¢broblasts were incu-
bated with 20 WM apigenin for 8, 16 and 24 h. Following 8 h
apigenin treatment, the basal levels of K1(I) collagen mRNA
remained unchanged. A noticeable decrease of K1(I) collagen
mRNA was observed following 16 h of apigenin treatment. A
maximal decrease of K1(I) collagen mRNA was observed at
24 h following apigenin treatment. Similarly, the apigenin
Fig. 1. Dose-dependent inhibition of cell proliferation by apigenin.
Subcon£uent myo¢broblasts in 24-well plates were treated with the
indicated concentrations of apigenin for 24 h. The cultures were
pulse-labeled with [3H]thymidine (0.5 Ci/well), washed and scintilla-
tion counted. Values are mean CPM+SE, n = 3. Results are repre-
sentative of two independent experiments. *P6 0.05 compared with
untreated cultures (C).
Fig. 2. E¡ect of apigenin on K1(I) collagen and K-smooth muscle
actin mRNA levels. Con£uent quiescent myo¢broblasts were treated
with 20 WM apigenin for 24 h and/or stimulated with TGF-L (1 ng/
ml) as indicated. Total RNA was isolated, resolved electrophoreti-
cally (10 Wg), and Northern blotted with probes for (A) K1(I) colla-
gen mRNA (B) K-smooth muscle actin mRNA or (C) 18S rRNA as
described. Results are representative of three independent experi-
ments.
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response was dose-dependent with a maximal decrease of
K1(I) collagen mRNA achieved at 20 WM apigenin (data not
shown).
The e¡ect of apigenin on K1(I) collagen mRNA levels was
further characterized by inhibiting protein synthesis with cy-
cloheximide. The addition of 5 WM cycloheximide did not
a¡ect basal K1(I) collagen mRNA levels. In myo¢broblasts
treated with cycloheximide, apigenin failed to induce a reduc-
tion of basal K1(I) collagen mRNA levels (Fig. 4).
To assess the stability of the K1(I) collagen mRNA, tran-
scription was blocked with actinomycin D. Without ongoing
transcription, K1(I) collagen mRNA decays with a half-life of
8^12 h [26]. Myo¢broblasts were treated with apigenin for 6 h
before transcription was blocked with actinomycin D. In my-
o¢broblasts incubated with the combination of apigenin and
actinomycin D, the rate of decline in the level of K1(I) colla-
gen mRNA was greater compared to myo¢broblasts that were
incubated with only actinomycin D (Fig. 5). These results
suggest that apigenin reduced the stability of the message.
The blots were stripped and re-probed for expression of
K-smooth muscle actin mRNA. We found that apigenin de-
creased the stability of the K-smooth muscle actin mRNA
(data not shown).
The e¡ect of apigenin on the rate of transcription was as-
sessed by nuclear run-on assays. Nuclei were isolated from
untreated and apigenin-treated myo¢broblasts. Basal levels
of K1(I) collagen transcription were not a¡ected by apigenin.
TGF-L induced an increase in K1(I) collagen transcription,
consistent with previous reports [26]. However, treatment
with apigenin inhibited this TGF-L-induced increase in the
rate of transcription of the K1(I) collagen gene. In addition,
apigenin did not a¡ect transcription of glyceraldehyde 3-phos-
phate dehydrogenase (Fig. 6). No hybridization was observed
with ¢lters containing plasmids without inserts (data not
shown).
To further investigate transcriptional activation, we used
the luciferase reporter construct p3TP-LUX that was engi-
neered to be responsive to TGF-L [27]. In myo¢broblasts
transfected with p3TP-LUX, TGF-L stimulates an increase
in luciferase activity. However, in apigenin-treated myo¢bro-
blasts TGF-L failed to stimulate the reporter construct (Fig.
7). These results along with the insensitivity of the TGF-L-
stimulated transcription of CTGF to apigenin demonstrate
that apigenin interferes with TGF-L-stimulated transcription
in a gene-speci¢c manner.
Fig. 4. E¡ect of cycloheximide on apigenin-induced decreases of
K1(I) collagen mRNA. Con£uent, quiescent myo¢broblasts were
treated with 5 WM cycloheximide (CHX) and apigenin (20 WM) for
24 h as indicated. Total RNA was isolated, resolved electrophoreti-
cally (10 Wg), and Northern blotted with probes for K1(I) collagen
mRNA or 18S rRNA as described.
Fig. 5. E¡ect of actinomycin D on the apigenin-induced steady-state
levels of K1(I) collagen mRNA. Con£uent, quiescent myo¢broblasts
were untreated or pre-treated with apigenin (20 WM) for 6 h. Acti-
nomycin D (5 WM) was added to the indicated cultures. Total RNA
was isolated at the indicated times, resolved electrophoretically
(10 Wg), and Northern blotted with probes for K1(I) collagen
mRNA or 18S rRNA as described. Results are representative of
three independent experiments.
Fig. 3. Kinetic studies following apigenin treatment. Con£uent, qui-
escent myo¢broblasts were treated with apigenin (20 WM) for the in-
dicated times in hours. Total RNA was isolated, resolved electro-
phoretically (10 Wg), and Northern blotted with probes for K1(I)
collagen mRNA or 18S rRNA as described. Results are representa-
tive of two independent experiments.
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Apigenin is a reported inhibitor of MAP kinase Erk1/2 [16].
To determine if apigenin regulated K1(I) collagen levels via
this pathway, we assessed the e¡ect of apigenin on the levels
of activated Erk1/2 in both quiescent and growth factor-
stimulated myo¢broblasts with Western blot analyses with
antibodies that detect phosphorylated Erk1/2. We did not
detect an increase in Erk1/2 activity at 10 min or at 16 h
following TGF-L stimulation. In addition, apigenin did not
induce a decrease in the basal levels of active Erk1/2. We
found that insulin stimulated an increase of Erk1/2 activity,
but apigenin induced only a modest attenuation. The blots
were stripped and re-probed with an antibody that detects
total Erk1/2. Treatment with apigenin did not alter expression
of Erk1/2 (Fig. 8).
The actinomycin studies (Fig. 5) indicate that apigenin re-
duces the stability of the K1(I) collagen mRNA. We previ-
ously reported a decrease of K1(I) collagen mRNA stability
in myo¢broblasts treated with the PI3K inhibitors wortman-
nin or LY294002[28]. Because the steady-state levels of
K-smooth muscle actin mRNA paralleled the steady-state
levels of K1(I) collagen mRNA, we investigated the relation-
ship between PI3K and the steady-state levels of K-smooth
muscle actin mRNA. To block PI3K activity, myo¢broblasts
were treated with LY294002. Northern blot analyses indicate
that basal levels and TGF-L-stimulated levels of K-smooth
muscle actin mRNA were decreased in LY294002-treated
myo¢broblasts (Fig. 9).
The data indicate that apigenin attenuated expression of
K1(I) collagen mRNA in part through decreased stability of
the message. We hypothesized that the change in steady-state
levels of K-smooth muscle actin mRNA may also be due to
decreased stability of the message and that the change in
stability may be mediated through decreased PI3K activity.
As a surrogate for PI3K activity, we monitored the levels of
active Akt by Western blot analyses with antibodies that de-
tect phospho-serine473-Akt. In quiescent myo¢broblasts, there
is a small amount of active Akt. Following treatment with
apigenin, the amount of active Akt is reduced. To demon-
strate that apigenin blocks growth factor-stimulated activa-
tion of Akt, myo¢broblasts were stimulated with insulin, a
growth factor that is known to activate PI3K and Akt. How-
ever, in apigenin-treated myo¢broblasts, insulin failed to acti-
Fig. 6. Nuclear run-on assay for K1(I) collagen. Con£uent, quiescent myo¢broblasts were pre-treated with 20 WM apigenin for 30 min, then
stimulated with TGF-L (1 ng/ml) as indicated for 16 h. Nuclei were harvested and the levels of transcription for K1(I) collagen and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) genes were assayed as described.
Fig. 7. Apigenin e¡ect on TGF-L-stimulated luciferase activity.
Myo¢broblasts were transiently transfected with the p3TP-LUX re-
porter construct in 6-well plates (1 Wg/well) using Lipofectamine
Plus according to manufacturer’s instructions. Myo¢broblasts were
untreated (C) or incubated with 20 WM apigenin for 10 min, then
stimulated with 1 ng/ml TGF-L as indicated. Luciferase activity/Wg
protein was determined after 6 h. Values are means of triplicates+
standard deviation, representative of four independent experiments.
Fig. 8. Phospho-Erk1/2 and total Erk1/2 levels following treatment
with apigenin. Con£uent, quiescent myo¢broblasts were treated with
apigenin at 20 WM and/or insulin (2 Wg/ml) for 16 h as indicated.
The cell layer was harvested and 100 Wg total protein was resolved
by PAGE as described. Blots were probed with an anti-phospho-
Erk1/2 antibody. Blots were stripped and re-probed with anti-
Erk1/2 antibody. Results are representative of two independent ex-
periments.
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vate Akt. The blots were stripped and re-probed with anti-Akt
antibody, demonstrating that the total amount of Akt was not
decreased by treatment with apigenin (Fig. 10).
4. Discussion
TGF-L plays a key role in the development of ¢brotic tis-
sues by inducing increased expression of matrix proteins, in-
cluding type I collagen. Depending on the cell type, TGF-L
stimulates an increase of K1(I) collagen mRNA levels by in-
creasing transcription of the K1(I) collagen gene and by in-
creasing the stability of the message [29]. The results of the
run-on assay (Fig. 6) clearly indicate that the TGF-L-stimu-
lated transcription of the K1(I) collagen gene is blocked by
apigenin. In addition, TGF-L did not stimulate transcription
from the p3TP-LUX reporter in apigenin-treated myo¢bro-
blasts. In contrast, the TGF-L-stimulated transcription of
CTGF is una¡ected in apigenin-treated myo¢broblasts.
Thus, it appears that apigenin disrupts TGF-L-stimulated
transcription in a gene-speci¢c manner. Apigenin does not
appear to disrupt signaling of receptor-activated SMAD3
since both CTGF and p3TP-LUX reporter transcription re-
quires SMAD3 [30^32]. Apigenin may block the activity of a
co-transcription factor such as AP-1. AP-1 binds SMAD3 and
modulates SMAD3-stimulated promoter activity in a number
of genes [33^35]. The transcription of 3TP-LUX is activated
by SMAD3 and AP-1 [27]. Depending on the cell type and the
stimulus, the transcription of the K1(I) collagen gene is acti-
vated or repressed by members of the AP-1 family of tran-
scription factors [36^41].
We found that apigenin largely inhibited the TGF-L-stimu-
lated induction of K1(I) collagen mRNA by blocking tran-
scription of the K1(I) collagen gene. However, TGF-L did
stimulate a modest increase of K1(I) collagen mRNA in api-
genin-treated myo¢broblasts. This residual activity may be
due to apigenin-insensitive mechanisms activated by TGF-L.
Alternatively, it is possible that the concentration of apigenin,
which was dictated by the limited solubility of apigenin in
aqueous solution, does not completely inactivate the mecha-
nisms that regulate mRNA stability.
Apigenin is known to inhibit PI3K [42]. Western analyses
con¢rmed that apigenin inhibited this pathway, as determined
by decreased phospho-serine473-AKT levels. We previously
reported that inhibition of PI3K by LY294002 or wortmannin
decreased K1(I) collagen mRNA levels through a mechanism
that involves reduced mRNA stability without changes in the
rate of transcription [28]. In the studies presented here, apige-
nin induced a decrease in K1(I) collagen mRNA stability and
a reduction of the levels of activated Akt, suggesting that
apigenin functions at least in part to decrease basal K1(I)
collagen mRNA levels through this mechanism. Apigenin
also blocked the TGF-L-induced increase in the rate of tran-
scription, indicating another regulatory mechanism. It appears
that TGF-L stimulates transcription of K1(I) collagen through
a PI3K-independent mechanism.
Apigenin is described as an inhibitor of MAP kinase, but
the available evidence supporting this function is not strong
[16]. Alterations in MAP kinase activity were reported by
others to in£uence K1(I) collagen mRNA levels either posi-
tively or negatively depending on the cell type [43,44]. We did
detect a modest decrease of activated Erk1/2 activity in hu-
man lung myo¢broblasts treated with apigenin. Moreover, we
found that basal and TGF-L-stimulated levels of K1(I) colla-
gen mRNA were not a¡ected by PD98059, the MAP kinase
kinase inhibitor (data not shown).
In the normal lung, interstitial ¢broblasts do not express
detectable levels of K-smooth muscle actin. Following lung
injury, ¢broblasts are activated and express cytoplasmic mi-
cro¢lament bundles containing K-smooth muscle actin. These
myo¢broblasts increase cell volume and produce large quan-
tities of type I collagen [45,46]. The di¡erentiation of the
Fig. 9. E¡ect of LY294002 on the TGF-L-stimulated increase of
K-smooth muscle actin mRNA. Con£uent, quiescent myo¢broblasts
were pre-treated with LY294002 (20 WM), and after 10 min, TGF-L
(1 ng/ml) was added to the cultures for 16 h as indicated. Total
RNA was isolated, resolved electrophoretically (10 Wg), and North-
ern blotted with probes for K-smooth muscle actin or 18S rRNA as
described. Results are representative of two independent experi-
ments.
Fig. 10. Phospho-serine473-AKT and total AKT levels following
treatment with apigenin. Con£uent, quiescent myo¢broblasts were
treated with apigenin (20 WM) and/or insulin (2 Wg/ml) for 16 h as
indicated. The cell layer was harvested and 100 Wg total protein was
resolved by PAGE as described. Blots were probed with an anti-
phospho-serine473-AKT antibody. Blots were stripped and re-probed
with anti-AKT antibody. Results are representative of two inde-
pendent experiments.
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myo¢broblast in the kidney, liver and other tissues is associ-
ated with the onset of ¢brogenesis [47^49]. TGF-L appears to
be important in regulating the myo¢broblast phenotype [49].
In the studies presented, the myo¢broblasts constitutively ex-
press low levels of K-smooth muscle actin mRNA and K1(I)
collagen mRNA. We ¢nd that apigenin down-regulates basal
K-smooth muscle actin and K1(I) collagen mRNA expression,
demonstrating that apigenin interfered with the appearance of
the myo¢broblast phenotype. Because the stability of K1(I)
collagen mRNA correlates with PI3K-Akt activity, we pro-
pose that maintenance of the myo¢broblast phenotype is de-
pendent on persistent PI3K activation.
Apigenin is a common dietary £avonoid that, unlike the
£avonoids quercetin and kaempferol, is non-toxic and non-
mutagenic [50,51]. Flavonoids are widely distributed through-
out the plant kingdom, as such they comprise a signi¢cant
component of the human diet. The average intake of the £a-
vonols, quercetin, myricetin and kaempferol, and the £avones,
luteolin and apigenin, in The Netherlands is 23 mg/day [52].
Dietary £avonoids were considered non-absorbable because
they are bound to sugars as L-glycosides. However, human
absorption of the quercetin glycosides from onions is twice
that of the pure aglycone [53]. Flavonoid intake from a nor-
mal diet is estimated to be 1 g/day, resulting in blood concen-
trations of 1^2 WM [54]. Apigenin is a relatively abundant
£avonoid present in fruits and vegetables such as parsley,
cherries, grapes, onions, and broccoli. The concentration of
apigenin used in our experiments is slightly greater than the
level of £avonoids found in blood in humans on a normal
diet. This suggests the possibility of in vivo activity from
£avonoids consumed in normal diets. In this study, we have
identi¢ed a novel molecular action of apigenin, that is, the
down-regulation of K1(I) collagen and K-smooth muscle
mRNAs. We suggest that dietary or supplemental consump-
tion of apigenin may modulate myo¢broblast activity in vivo.
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